Control of human mesothelin-expressing tumors by DNA vaccines
- 21 June 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 14 (16), 1189-1198
- https://doi.org/10.1038/sj.gt.3302974
Abstract
Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma. In the current study, we utilized a DNA vaccine encoding human mesothelin (pcDNA3-Hmeso) to treat C57BL/6 mice challenged with luciferase-expressing, Hmeso-expressing ovarian cancer cell line, Defb29 Vegf-luc/Hmeso. The therapeutic effect of the tumor-challenged mice was followed by noninvasive bioluminescence imaging systems. The mechanism of the antitumor effect was characterized by depletion of subsets of lymphocytes as well as adopted transfer of serum from pcDNA3-Hmeso-vaccinated mice. We found that vaccination with pcDNA3-Hmeso DNA vaccine generates a significant antitumor effect and promotes survival in mice challenged with Defb29 Vegf-luc/Hmeso. Furthermore, we found CD4+ and CD8+ T-cell immune responses as well as the humoral immune responses are important for the observed antitumor effects in vaccinated mice. Our data indicated that vaccination with DNA vaccine targeting Hmeso could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibody-mediated immunity.Keywords
This publication has 39 references indexed in Scilit:
- A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumorsVaccine, 2007
- Vaccinia virus preferentially infects and controls human and murine ovarian tumors in miceGene Therapy, 2006
- Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous CarcinomaClinical Cancer Research, 2006
- Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer PatientsClinical Cancer Research, 2005
- MesothelinClinical Cancer Research, 2004
- Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her‐2/neuInternational Journal of Cancer, 2003
- HPV DNA vaccinesFrontiers in Bioscience-Landmark, 2003
- Tumor immunity and autoimmunity induced by immunization with homologous DNA.JCI Insight, 1998
- DNA VACCINESAnnual Review of Immunology, 1997
- Exposing the immunology of naked DNA vaccinesImmunity, 1995